

ACDIMA, SK Plasma sign USD 330 mn MoU

South Korea's SK Plasma signed a memorandum of understanding worth USD 330 million with Egypt's state-run pharmaceutical company ACDIMA for the establishment of a blood product plant and the transfer of related technology. SK Plasma will now contract manufacture plasma-derived medical products using 1 million liters of Egyptian plasma at its facility in South Korea.